Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473394 · ClinicalTrials.gov registry record · Phase 4
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
A Phase 4 study of Major Depressive Disorder, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 518
- Enrollment target
- 14
- Study locations
NCT01473394 is a Phase 4 study of Major Depressive Disorder that has completed, run by Forest Laboratories. The registered enrollment target is 518 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (38% higher). The trial reports 14 study locations across 10 states.
The verdict
NCT01473394, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 518 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
Conditions Studied
Interventions
- DRUG Vilazodone
- DRUG Dose-matched placebo
Study Locations (14)
California
- Forest Investigative Site 009 - Beverly Hills
- Forest Investigative Site 003 - Encino
- Forest Investigative Site 010 - New Port Beach
Florida
- Forest Investigative Site 005 - Jacksonville
- Forest Investigative Site 004 - Orlando
Washington
- Forest Investigative Site 006 - Bellevue
- Forest Investigative Site 013 - Seattle
Georgia
- Forest Investigative Site 012 - Atlanta
Maryland
- Forest Investigative Site 001 - Baltimore
Ohio
- Forest Investigative Site 002 - Dayton
Pennsylvania
- Forest Investigative Site 011 - Philadelphia
Rhode Island
- Forest Investigative Site 015 - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473394
The ClinicalTrials.gov registry entry for NCT01473394 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (38% higher). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Vilazodone is the first listed.
NCT01473394 reports 14 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Washington.
Frequently Asked Questions
What is clinical trial NCT01473394 about?
NCT01473394 is a clinical study titled "Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder". The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
What is the current status of trial NCT01473394?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 518 participants. The study started on 2011-12. Estimated completion is 2013-02.
What conditions does trial NCT01473394 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT01473394?
The interventions under investigation include: Vilazodone (DRUG), Dose-matched placebo (DRUG).
Who is sponsoring clinical trial NCT01473394?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01473394 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.